QTERNMET XR FDA approval date

The FDA approved QTERNMET XR on 2 May 2019.

FDA approval date
2 May 2019

Drug identity has not yet been verified against registry records

Also recorded as DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2019-05-02DayQTERNMET XRFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA210874", "applicant_as_listed_by_fda": "ASTRAZENECA AB", "brand_names": ["QTERNMET XR"], "active_ingredients": ["DAPAGLIFLOZIN", "METFORMIN HYDROCHLORIDE", "SAXAGLIPTIN HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190502", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026